How would you approach systemic therapy in a postmenopausal female with previous early stage ER/PR positive IDC, on anastrozole, with new isolated metastatic disease that remains strongly ER/PR positive?

Specifically, this patient had a new left lacrimal gland metastatic lesion that developed four years from her initial diagnosis and is currently undergoing proton therapy to this lesion. No other evidence of disease with imaging.

Answer from: Medical Oncologist at Academic Institution

For the typical patient with disease recurrence (and measurable or evaluable disease) on adjuvant AI, the standard of care would be to switch endocrine therapies, usually from the AI to fulvestrant, and add a cdk 4/6 inhibitor, though simply adding the cdk 4/6 inhibitor to the AI would also be reaso...

Please select the option that best describes you:

How would you approach systemic therapy in a postmenopausal female with previous early stage ER/PR positive IDC, on anastrozole, with new isolated metastatic disease that remains strongly ER/PR positive?

Related Questions